Drug Profile

Docetaxel - Meridian Lab

Alternative Names: Captisol-enabled® docetaxel; ML-061

Latest Information Update: 12 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Meridian Lab
Class Antineoplastics; Small molecules; Taxanes
Mechanism of Action

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Registered Breast cancer; Gastric cancer; Non-small cell lung cancer; Prostate cancer; Squamous cell cancer

Most Recent Events

12 Dec 2025 Docataxel is still registered for Gastric Cancer in the US
12 Dec 2025 Docataxel is still registered for Squamous cell carcinoma in the US
11 Dec 2025 Docataxel is still registered for Breast cancer, Non-small cell lung cancer, Prostate cancer in the US

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com